Grzegorz Satała

Grzegorz Satała

Auto-generated profile, based on publicly available information

Grzegorz Satała

Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Kraków, Poland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PZPaweł Zajdel
Paweł Zajdel
Krzysztof MarciniecKrzysztof Marciniec
Krzysztof Marciniec
AMAndrzej Maślankiewicz
Andrzej Maślankiewicz
KGKatarzyna Grychowska
Katarzyna Grychowska
GSGrzegorz Satała
Grzegorz Satała
MPMaciej Pawłowski
Maciej Pawłowski

5 May 2016 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
KGKatarzyna Grychowska
Katarzyna Grychowska
GSGrzegorz Satała
Grzegorz Satała
TKTomasz Kos
Tomasz Kos
APAnna Partyka
Anna Partyka
ECEvelina Colacino
Evelina Colacino
PZPaweł Zajdel
Paweł Zajdel

1 February 2012 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
PZPawel Zajdel
Pawel Zajdel
Krzysztof MarciniecKrzysztof Marciniec
Krzysztof Marciniec
AMAndrzej Maślankiewicz
Andrzej Maślankiewicz
GSGrzegorz Satała
Grzegorz Satała
BDBeata Duszyńska
Beata Duszyńska
MPMaciej Pawłowski
Maciej Pawłowski

14 August 2014 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
AWAnna Waszkielewicz
Anna Waszkielewicz
KPKarolina Pytka
Karolina Pytka
ARAnna Rapacz
Anna Rapacz
EWElżbieta Wełna
Elżbieta Wełna
MJMonika Jarzyna
Monika Jarzyna
HMHenryk Marona
Henryk Marona

1 October 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PZPawel Zajdel
Pawel Zajdel
RKRafał Kurczab
Rafał Kurczab
KGKatarzyna Grychowska
Katarzyna Grychowska
GSGrzegorz Satała
Grzegorz Satała
MPMaciej Pawłowski
Maciej Pawłowski
ABAndrzej Bojarski
Andrzej Bojarski

1 September 2023 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
KKKat Fenris Kiilerich
Kat Fenris Kiilerich
JLJoe Lorenz
Joe Lorenz
MSMalthe B. Scharff
Malthe B. Scharff
NSNikolaj Speth
Nikolaj Speth
TBTobias G. Brandt
Tobias G. Brandt
MPMikael Palner
Mikael Palner
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report increases in mental health, yet such reports are often highly biased and vulnerable to placebo effects. Here we establish and validate a psilocybin microdose-like regimen in rats with repeated low doses of psilocybin administration at a dose derived from occupancy at rat brain 5-HT2A receptors in vivo. The rats tolerated the repeated low doses of psilocybin well and did not manifest signs of anhedonia, anxiety, or altered locomotor activity. There were no deficits in pre-pulse inhibition of the startle reflex, nor did the treatment downregulate or desensitize the 5-HT2A receptors. However, the repeated low doses of psilocybin imparted resilience against the stress of multiple subcutaneous injections, and reduced the frequency of self-grooming, a proxy for human compulsive actions, while also increasing 5-HT7 receptor expression and synaptic density in the paraventricular nucleus of the thalamus. These results establish a well-validated regimen for further experiments probing the effects of repeated low doses of psilocybin. Results further substantiate anecdotal reports of the benefits of psilocybin microdosing as a therapeutic intervention, while pointing to a possible physiological mechanism.